Interleukin-10 (Interleukin 10)

Subscribe to Selected New Research on Interleukin-10

7444 relevant articles (322 outcomes, 933 trials/studies) found for this Bio-Agent

Description: A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein.

Also Known As:

Interleukin 10; IL10; IL-10; CSIF-10; Cytokine Synthesis Inhibitory Factor; Cytokine formation-inhibiting factor (mouse clone F115 protein moiety reduced)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tsai, Fuu-Jen: 8 articles (03/2007 - 01/2003)
2.	Wang, Xiao-Zhong: 7 articles (10/2007 - 03/2003)
3.	Zhang, Li-Juan: 7 articles (10/2007 - 03/2003)
4.	Moldawer, Lyle L: 7 articles (12/2005 - 01/2002)
5.	Cohard, M: 7 articles (02/2002 - 12/2000)
6.	Chen, Zhi-Xin: 6 articles (10/2007 - 03/2003)
7.	Rutgeerts, P: 6 articles (02/2002 - 12/2000)
8.	Link, H: 6 articles (10/2001 - 09/2000)
9.	Flavell, Richard A: 5 articles (04/2008 - 09/2006)
10.	Wynn, Thomas A: 5 articles (03/2008 - 03/2002)

Related Diseases

1.	Infection 08/01/2007 - "This study evaluated associations between three single nucleotide polymorphisms in the IL10 promoter and clearance of low- or high-risk HPV infection in a cohort of 226 largely HIV-1-infected African-American adolescent females. " 12/23/2008 - "As a result, simultaneous blockade of IL-10 and PD-L1 was significantly more effective in restoring antiviral T-cell responses than blockade of either alone, and led to substantially enhanced control of an established persistent viral infection. " 06/01/1996 - "In vivo neutralization of IL-10 in BALB/c mice with an anti-IL-10 mAB during MoPn infection significantly increased the DTH response and enhanced clearance of MoPn. " 10/15/2008 - "Using Mycobacterium tuberculosis-susceptible CBA/J mice, we show that blocking the action of IL-10 in vivo during chronic infection stabilized the pulmonary bacterial load and improved survival. " 07/01/2008 - "In interleukin-10 knock out (IL-10 KO) mice, accelerated clearance of pulmonary Chlamydia pneumoniae infection was observed. " Order ALL the reference details at left...
2.	Inflammation 04/01/1998 - "Treatment with IL-10 resulted in a marked improvement in intestinal inflammation. " 02/01/2008 - "Treatment with allergen-modified-DC suppressed airway inflammation and Th2 responses, and increased IL-10 and IFN-gamma production and Foxp3(+) Tregs significantly; and eliminated the responses of CD4(+) T cells to allergen. " 01/01/2002 - "Fact, that IL-10 is produced by Th1 and that inhibits cytokine production by Th2 lymphocytes has led to the concept that IL-10 might be beneficial in mitigating allergic inflammation. " 10/01/1999 - "In conclusion, reducing the inflammatory response to SCI by systemic administration of IL-10 resulted in a significant reduction in neuronal damage, suggesting that targeting injury-induced inflammation may be an effective treatment strategy for acute SCI." 01/01/2000 - "These findings indicate that exogenous IL-10 is effective in reducing airway inflammation and airway hyperreactivity due to the inhalation of CDE." Order ALL the reference details at left...
3.	Colitis 08/01/2004 - "This study investigates the therapeutic efficacy of an adenovirus encoding IL-10 (AdvmuIL-10) in the treatment of experimental colitis. " 12/01/2002 - "This study investigates the therapeutic efficacy of an adenoviral vector encoding IL-10 (AdvmuIL-10) in experimental colitis. " 02/01/2009 - "We hypothesized that interleukin-10 delivery to the distal gastrointestinal tract using a unique delivery vehicle may serve as a novel therapeutic for the treatment of experimental colitis. " 12/01/2006 - "Intragastric administration of Lactococcus lactis genetically modified to secrete IL-10 in situ in the intestine was shown to be effective in healing and preventing chronic colitis in mice. " 09/01/2004 - "Lactobacillus reuteri is effective in inhibiting colitis in interleukin-10 (IL-10)-deficient mice. " Order ALL the reference details at left...
4.	Neoplasms (Cancer) 10/01/2009 - "Therefore, the present study was designed to evaluate the association of TNFA (-308G>A) and IL-10 (-819C>T) gene polymorphism with risk of cervical cancer. " 08/01/2009 - "Collectively, these studies indicate that IL-10 immunoadhesins, especially in monomeric form, are potent inhibitors of biological activities of IL-10 and suggest that these molecules, alone or in conjunctions with other immunotherapeutic approaches, can be utilized for the immuno-targeting of IL-10 producing tumors." 01/01/2009 - "Some studies indicate that IL-10 concentration correlates with the tumor burden and can thus predict the surgical outcome. " 01/01/2009 - "By studying the kinetics of IL-10 concentrations prior to and after surgery, this study attempts to reveal once more the ability of tumor micro-environment to produce IL-10. " 04/01/2007 - "In addition, these studies suggest that the IL-10 expression by malignant B cells may not only suppress anti-tumor T cell responses in vivo, but also promote the survival of malignant B cells despite treatment with chemotherapeutic agents." Order ALL the reference details at left...
5.	Necrosis 10/01/2003 - "Interleukin 10 gene transfection of donor lungs ameliorates posttransplant cell death by a switch from cellular necrosis to apoptosis." 10/01/2004 - "In this study, we investigated whether strain CR1 caused apoptosis or necrosis of macrophages after its inoculation into mice peritoneal cavity, and whether this correlated with the secretion of IL-10. " 09/15/2003 - "In this study, we show that IL-10 knockout mice infected with this parasite develop extensive areas of coagulative necrosis in the liver, and newborn larvae are required for lesion formation. " 03/01/2003 - "In in vitro cell cultures, there was reduced tumour necrosis factor-alpha and interleukin-10 production at week 26, with the latter persistent throughout the study period. " 09/01/2009 - "We showed that IL-32beta expression was increased in a time-dependent manner in monocyte-derived DC upon LPS treatment and peaked at 24 hr. Production of IL-10 was exactly coincident with IL-32beta expression, but IL-1beta and tumour necrosis factor-alpha production peaked at 6 hr after LPS treatment, then steeply declined. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Cytokines
3.	Interleukin-6 (Interleukin 6)
4.	Interleukin-4 (Interleukin 4)
5.	Interleukin-12 (IL 12)
6.	Interferon-gamma (Interferon, gamma)
7.	Interleukin-10 (Interleukin 10)
8.	Interleukin-2 (IL2)
9.	Interleukins
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Aftercare (After-Treatment)
3.	Immunotherapy
4.	Drug Therapy (Chemotherapy)
5.	Ligation

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>